John-Claude Saltiel, MBA
Vice President of Corporate Development
John-Claude Saltiel joined NeuroTrauma Sciences in April 2018 as Vice President of Corporate Development and General Manager of the company’s subsidiary NeurExo Sciences. He brings more than 25 years of health care and life sciences experience, having advised on and implemented large, complex corporate initiatives as a strategy and management consultant, with a specialization in product launch and positioning, managed markets, operational excellence, and M&A strategy and integration. John-Claude served as a member of a team that helped successfully launch Multiple Sclerosis and Rheumatoid Arthritis biologic products, and while at Alexion Pharmaceuticals, as part of the Corporate Project Management Office, he managed the global launch of its blockbuster Soliris’ line extension into the refractory generalized myasthenia gravis market. John-Claude graduated with a B.S. from Boston University and an M.B.A. in Finance and Management from Columbia Business School.